The Network for Excellence in Neuroscience Clinical Trials, or NeuroNEXT, was created to conduct studies of treatments for neurological diseases through partnerships with academia, private foundations, and industry. The network is designed to expand the National Institute of Neurological Disorders and Stroke's (NINDS) capability to test promising new therapies, increase the efficiency of clinical trials before embarking on larger studies, and respond quickly as new opportunities arise to test promising treatments for people with neurological disorders.
Goals of the NeuroNEXT program:
There are 25 sites in the United States that are a part of the NeuroNEXT network. Karen S. Marder, MD, MPH and Claudia A. Chiriboga, MD, MPH are the co-PIs at NewYork-Presbyterian/Columbia University Medical Center and Claire Henchcliffe, M.D., D.Phil. is the site PI at NewYork-Presbyterian/Weill Cornell Medical Center.